GYNECOLOGIC CANCERS

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA- 1 trial.

Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the identification and treatment of ovarian cancer.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.

Mark A. Morgan, MD, discusses the role of robotic surgery in gynecologic cancer.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Russell J. Schilder, MD, discusses the GOG-9929 trial.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an overview of screening for ovarian cancer.

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib (Iclusig), following the high occurrence of arterial thrombosis in patients treated with the drug.

Michael Birrer, MD, PhD, discusses the role of PARP inhibitors in ovarian cancer.

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.

Don S. Dizon, MD, FACP, Medical Gynecologic Oncologist, Director of the Oncology Sexual Health Clinic, Massachusetts General Hospital, gives an update on targeted therapies for the treatment of patients with ovarian cancer.

Over the past two decades, there has been a shift away from indiscriminate cell-killing by anticancer agents toward the development of more specific drugs that target key aspects of cancer cell biology.

A phase III clinical program to investigate olaparib as a treatment for patients with BRCA-mutated ovarian cancer marks a step forward in the revived development of an agent that was once left on the sidelines.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses the utility for vinegar as a screening tool in the U.S.

Measuring CA-125, the protein that predicts ovarian cancer recurrence, has shown promise as a screening tool for the disease.

Paul A. Bunn, Jr, MD, from the University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor mutation.

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Pazopanib was better tolerated with noninferior efficacy when compared to sunitinib as a treatment for patients with advanced renal cell carcinoma.